Tamoxifen: Five versus ten years - Is the end in sight?

Journal of the National Cancer Institute

Volumn 93, Issue 9, 2001, Pages 662-664

  Abrams, Jeffrey S ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; EXEMESTANE; LETROZOLE; PLACEBO; TAMOXIFEN;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RESEARCH; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EDITORIAL; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT INDICATION;

EID: 0035795711     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/93.9.662     Document Type: Editorial

References (22)

1. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial
2. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors
3. Adjuvant chemotherapy for breast cancer
4. Effect of a National Cancer Institute Clinical Alert on breast cancer practice patterns
5. Tamoxifen for early breast cancer: An overview of the randomized trials
6. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women
7. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14
8. Tamoxifen: Trials, tribulations, and trade-offs
9. Scientific review of tamoxifen. Overview from a medical oncologist
10. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors
11. Early stopping of a clinical trial when there is evidence of no treatment benefit: Protocol B-14 of the National Surgical Adjuvant Breast and Bowel Project
12. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer
13. Five years of tamoxifen - Or more?
14. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer
15. Tamoxifen adjuvant treatment duration in early breast cancer: Initial results of a randomized study comparing short-term treatment with long-term treatment
16. Scottish Adjuvant Tamoxifen Trial: A randomized study updated to 15 years
17. The optimal duration of adjuvant tamoxifen treatment for breast cancer remains uncertain: Randomize into aTTom
18. Anastrozole is superior to tamoxifen in first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial
19. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: A randomized study